Clinical trials
Resectable Esophageal Squamous Cell Carcinoma clinical trials
Below are recruiting resectable esophageal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 116 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06413342RecruitingPhase 2
Sintilimab after chemoradiation for older adults with esophageal cancer
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Hangzhou, ZhejiangAges 70–85 - NCT06354140RecruitingPhase 2
Tislelizumab plus S-1 for esophageal cancer after surgery
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07808853RecruitingPhase 2
Short radiation plus chemo-immunotherapy before esophageal cancer surgery
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
Guanzhou, GuangdongAges 18–75 - NCT04481256Recruiting
Immunotherapy with chemoradiation for esophageal cancer
This trial tests adding medicines that block TGF-beta and PD-L1 to standard chemoradiation for esophageal squamous cell cancer that can’t be removed with surgery. It aims to improve control of the cancer where it sits, while keeping treatment safe.
AmsterdamAges 18 years+ - NCT07796113RecruitingPhase 2
Study of adebrelimab plus famitinib and chemo before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Xi'an, ShannxiAges 18–75 - NCT06563869RecruitingPhase 3
Sintilimab with chemo and growth factor before esophageal cancer surgery
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
Nanjing, JiangsuAges 18–75 - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT07751055RecruitingPhase 2
Chemotherapy and radiation with immunotherapy before surgery for esophageal cancer
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
Guangzhou, GuangdongAges 18–75 - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70 - NCT06602843Recruiting
Chemoimmunotherapy before and after surgery for esophageal cancer
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
HefeiAges 18–75 - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT07699185RecruitingPhase 2
Immunotherapy plus chemoradiation before surgery for esophageal cancer
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Wuhan, HubeiAges 18–75 - NCT07638436RecruitingPhase 2
Immunotherapy with chemotherapy for advanced esophageal cancer
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07629817RecruitingPhase 3
Surgery vs. Chemoradiation for Esophageal Cancer
This trial compares surgery versus a strong combination of chemotherapy and radiation for people with esophageal squamous cell carcinoma that has been treated first with immunotherapy. It aims to find which approach leads to better outcomes after the initial immunotherapy and chemotherapy.
Zhengzhou, HenanAges 18–75 - NCT07622797RecruitingPhase 2
Immunotherapy with chemotherapy and radiation for esophageal cancer
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Luoyang, HenanAges 18 years+ - NCT06710665Recruiting
Predicting adjuvant therapy success after esophageal cancer surgery
This trial looks at how well the tumor responded to chemotherapy or radiation before surgery, to see if that can help doctors decide next steps like additional treatment. It may help people with esophageal squamous cell cancer who had the tumor removed completely after initial therapy.
Fuzhou, FujianAges 18 years+ - NCT07595770RecruitingPhase 2
New immunotherapy combined with chemotherapy and radiation for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05214222RecruitingPhase 2
New treatment for advanced esophageal cancer after past therapy
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
Guangzhou, GuangdongAges 18–75 - NCT07530094RecruitingPhase 2
Radiation and chemotherapy with immunotherapy for advanced esophageal cancer
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07505186RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Hangzhou, ChinaAges 18–75 - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT06489197RecruitingPhase 2
AK112 plus chemo for advanced esophageal cancer
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable esophageal squamous cell carcinoma?
- Yes. Clin2 currently lists 116 recruiting resectable esophageal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable esophageal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable esophageal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Esophageal Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Resectable Head and Neck Squamous Cell Carcinoma
- Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
- Metastatic Esophageal Squamous Cell Carcinoma
- Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
- Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.